These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 38831540)
1. Exploring the Molecular Therapeutic Mechanisms of Gemcitabine through Quantitative Proteomics. Jiang Y; Ren X; Zhao J; Liu G; Liu F; Guo X; Hao M; Liu H; Liu K; Huang H J Proteome Res; 2024 Jul; 23(7):2343-2354. PubMed ID: 38831540 [TBL] [Abstract][Full Text] [Related]
2. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594 [TBL] [Abstract][Full Text] [Related]
3. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205. Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008 [TBL] [Abstract][Full Text] [Related]
4. YAP-LAMB3 axis dictates cellular resistance of pancreatic ductal adenocarcinoma cells to gemcitabine. Li Y; Wang X; Yu H; Cao J; Xie J; Zhou J; Feng Z; Chen W Mol Carcinog; 2024 Oct; 63(10):1953-1966. PubMed ID: 39016677 [TBL] [Abstract][Full Text] [Related]
5. Proteomic analysis of gemcitabine-induced drug resistance in pancreatic cancer cells. Chen YW; Liu JY; Lin ST; Li JM; Huang SH; Chen JY; Wu JY; Kuo CC; Wu CL; Lu YC; Chen YH; Fan CY; Huang PC; Law CH; Lyu PC; Chou HC; Chan HL Mol Biosyst; 2011 Nov; 7(11):3065-74. PubMed ID: 21894339 [TBL] [Abstract][Full Text] [Related]
6. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. de Sousa Cavalcante L; Monteiro G Eur J Pharmacol; 2014 Oct; 741():8-16. PubMed ID: 25084222 [TBL] [Abstract][Full Text] [Related]
7. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts. Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568 [TBL] [Abstract][Full Text] [Related]
8. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma. Ma L; Fan Z; Du G; Wang H Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935 [TBL] [Abstract][Full Text] [Related]
9. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations. Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338 [TBL] [Abstract][Full Text] [Related]
10. TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC. Huang W; Hu X; He X; Pan D; Huang Z; Gu Z; Huang G; Wang P; Cui C; Fan Y Drug Resist Updat; 2024 May; 74():101079. PubMed ID: 38518727 [TBL] [Abstract][Full Text] [Related]
11. Resistance to gemcitabine is mediated by the circ_0036627/miR-145/S100A16 axis in pancreatic cancer. Yu S; Wang M; Zhang H; Guo X; Qin R J Cell Mol Med; 2024 Jun; 28(12):e18444. PubMed ID: 38924205 [TBL] [Abstract][Full Text] [Related]
12. S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway. Liu Y; Bi T; Liu L; Gao Q; Shen G; Qin L Naunyn Schmiedebergs Arch Pharmacol; 2019 May; 392(5):615-622. PubMed ID: 30683944 [TBL] [Abstract][Full Text] [Related]
13. Alteration of the intrinsic apoptosis pathway is involved in Notch-induced chemoresistance to gemcitabine in pancreatic cancer. Du X; Zhao YP; Zhang TP; Zhou L; Chen G; Wang TX; You L; Shu H Arch Med Res; 2014 Jan; 45(1):15-20. PubMed ID: 24316112 [TBL] [Abstract][Full Text] [Related]
14. Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells. Duong HQ; Hwang JS; Kim HJ; Kang HJ; Seong YS; Bae I Int J Oncol; 2012 Sep; 41(3):855-61. PubMed ID: 22710732 [TBL] [Abstract][Full Text] [Related]
15. Effect of a combination of S-1 and gemcitabine on cell cycle regulation in pancreatic cancer cell lines. Morimoto Y; Takeuchi O; Takizawa A; Yoneyama H; Asanuma F; Suzuki Y; Atsuda K; Yamada Y Anticancer Drugs; 2012 Jun; 23(5):505-14. PubMed ID: 22334000 [TBL] [Abstract][Full Text] [Related]
16. Pancreatic cancer cells spectral library by DIA-MS and the phenotype analysis of gemcitabine sensitivity. Kong R; Qian X; Ying W Sci Data; 2022 Jun; 9(1):283. PubMed ID: 35680938 [TBL] [Abstract][Full Text] [Related]
17. Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer. Fan K; Fan Z; Cheng H; Huang Q; Yang C; Jin K; Luo G; Yu X; Liu C Cancer Med; 2019 Oct; 8(13):5903-5915. PubMed ID: 31426130 [TBL] [Abstract][Full Text] [Related]
18. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer. Pan MR; Hsu MC; Luo CW; Chen LT; Shan YS; Hung WC Oncotarget; 2016 Sep; 7(38):61136-61151. PubMed ID: 27531902 [TBL] [Abstract][Full Text] [Related]
19. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors. Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368 [TBL] [Abstract][Full Text] [Related]
20. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells. Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]